Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia; Cardiovascular Institute, Epworth Healthcare, Melbourne, Victoria, Australia.
Department of Cardiology, Alfred Hospital, Melbourne, Victoria, Australia.
Am J Cardiol. 2019 Oct 1;124(7):1085-1090. doi: 10.1016/j.amjcard.2019.06.026. Epub 2019 Jul 15.
Limited data exist regarding transcatheter aortic valve implantation (TAVI) in nonagenarians. This study evaluates the short- and mid-term outcomes of nonagenarians after TAVI. Between 2008 and 2017, all patients who underwent TAVI in 2 centers in Australia were prospectively included in a registry and followed-up for 5 years. Outcomes were based on VARC-2 criteria. Additionally, the patient's reliance on daily living support at 1 year was evaluated. Of the 588 patients, 71 (12.1%) were ≥90 years old (mean age 92.2 ± 2 vs 83.2 ± 6 years in <90-year-old patients), with a median STS-PROM score of 5.7 (vs 3.9 in <90-year-old patients, odds ratio [OR] 1.07, 95% confidence interval 1.01 to 1.13, p = 0.02) and a median clinical frailty score of 4 (vs 4 <90-year-old patients, OR 0.88, p = 0.44). Mortality was 0% in ≥90-year-old patients at 30 days (vs 1.4% in <90-year-old patients; p = 0.82) and 12% at 1 year (vs 7.4%, in <90-year-old patients; hazard ratio 1.64, p = 0.20). There were no significant differences in periprocedural complications and mortality at 5 years between the 2 groups. At 1 year, nonagenarians were significantly more likely to live in an aged-care facility compared with <90-year-old patients (25% vs 16%, OR 5.99, 95% confidence interval 2.62 to 13.67, p <0.001). In conclusion, carefully selected nonagenarians have excellent short- and mid-term outcomes post-TAVI and should therefore not be refused based on age alone. Nevertheless, the significantly higher rate of transfer to an aged-care facility highlights the importance of a more refined frailty assessment before TAVI than the currently widely used clinical frailty score.
关于 90 岁以上患者行经导管主动脉瓣置换术(TAVI)的数据有限。本研究评估了两家澳大利亚中心的 90 岁以上患者 TAVI 后的短期和中期结果。2008 年至 2017 年,在澳大利亚的 2 家中心前瞻性纳入所有接受 TAVI 的患者,并进行了 5 年随访。结果基于 VARC-2 标准。此外,还评估了患者在 1 年时对日常生活支持的依赖程度。在 588 名患者中,71 名(12.1%)≥90 岁(平均年龄 92.2 ± 2 岁与<90 岁患者的 83.2 ± 6 岁相比),中位 STS-PROM 评分为 5.7(<90 岁患者为 3.9,比值比 [OR] 1.07,95%置信区间 1.01 至 1.13,p=0.02),中位临床虚弱评分 4(<90 岁患者为 4,OR 0.88,p=0.44)。≥90 岁患者的 30 天死亡率为 0%(<90 岁患者为 1.4%;p=0.82),1 年死亡率为 12%(<90 岁患者为 7.4%;危险比 1.64,p=0.20)。两组患者在 5 年时的围手术期并发症和死亡率无显著差异。1 年时,与<90 岁患者相比,90 岁以上患者更有可能居住在养老院(25%比 16%,OR 5.99,95%置信区间 2.62 至 13.67,p<0.001)。总之,精心挑选的 90 岁以上患者 TAVI 后有极好的短期和中期结果,因此不应仅因年龄而拒绝 TAVI。然而,转至养老院的比例明显较高,突显了 TAVI 前进行更精细虚弱评估的重要性,而不仅仅是目前广泛使用的临床虚弱评分。